Drug intelligence / Profile preview

SPX10624258

Development stage: Preclinical
Lead developer: Spherix Global Insights
Modality: Small Molecules

Overview

**SPX10624258 (SPX106)** is a preclinical small molecule compound licensed by Spherix from the University of Kentucky, investigated primarily for the treatment of dyslipidemia, including hypertriglyceridemia and hypercholesterolemia. In preclinical studies using LDLr-/- mouse models, it significantly reduced serum triglycerides by 36% and cholesterol by 19% when administered in combination with D-tagatose over nine weeks, prompting further evaluation both as monotherapy and in combination for high triglycerides, atherosclerosis, and metabolic syndrome. The company planned human proof-of-concept trials pending an IND filing around 2012, but no further clinical advancement is documented in available sources.[1][4][5]

Beyond the preview

Go deeper on SPX10624258.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPX10624258.

Explore the full profile